Programmed death-1 & its ligands: Promising targets for cancer immunotherapy

Rajeev Kumar Shrimali, John Edward Janik, Rasha Abu-Eid, Mikayel Mkrtichyan, Samir N. Khleif

Research output: Contribution to journalReview article

10 Scopus citations

Abstract

Novel strategies for cancer treatment involving blockade of immune inhibitors have shown significant progress toward understanding the molecular mechanism of tumor immune evasion. The preclinical findings and clinical responses associated with programmed death-1 (PD-1) and PD-ligand pathway blockade seem promising, making these targets highly sought for cancer immunotherapy. In fact, the anti-PD-1 antibodies, pembrolizumab and nivolumab, were recently approved by the US FDA for the treatment of unresectable and metastatic melanoma resistant to anticytotoxic T-lymphocyte antigen-4 antibody (ipilimumab) and BRAF inhibitor. Here, we discuss strategies of combining PD-1/PD-ligand interaction inhibitors with other immune checkpoint modulators and standard-of-care therapy to break immune tolerance and induce a potent antitumor activity, which is currently a research area of key scientific pursuit.

Original languageEnglish (US)
Pages (from-to)777-792
Number of pages16
JournalImmunotherapy
Volume7
Issue number7
DOIs
Publication statusPublished - Jan 1 2015

    Fingerprint

Cite this

Shrimali RK, Janik JE, Abu-Eid R, Mkrtichyan M, Khleif SN. Programmed death-1 & its ligands: Promising targets for cancer immunotherapy. Immunotherapy. 2015 Jan 1;7(7):777-792. https://doi.org/10.2217/imt.15.49